Advertisement

Cost-effectiveness analysis of preoperative treatment of acromegaly with somatostatin analogue on surgical outcome

Published:August 20, 2015DOI:https://doi.org/10.1016/j.ejim.2015.07.019

      Highlights

      • Treatment for acromegaly includes neurosurgery, radiotherapy and medical therapy.
      • The high costs associated mandate that cost-effective delivery be considered.
      • Preoperative medical treatment improves surgical results in particular centres.
      • Preoperative medical treatment is highly cost-effective in particular centres.

      Abstract

      Context

      There is no uniform standard of care for acromegaly. Due to the high costs involved, steps must be taken to ensure the cost-effective delivery of treatment.

      Objective

      Taking the results of an earlier meta-analysis as a starting point, this study aims to determine whether treatment with long-acting somatostatin analogue (SSA) prior to surgery improves the cost-effectiveness of the treatment of acromegaly.

      Methods

      The results are presented as an Incremental Cost Effectiveness Ratio (ICER) immediately after surgery, for the following year and over the next four decades. The cure rates percentage (95% CI) for the three randomized prospective controlled trials were 44.4% (34.2–54.7) and 18.2% (10.1–26.3) for preoperative treated and untreated patients respectively. The cost of pharmacological treatments was based on the number of units prescribed, dose and length of treatment.

      Results

      The mean (95% CI) ICER immediately after surgery was €17,548 (12,007–33,250). In terms of the postoperative SSA treatment, the ICER changes from positive to negative before two years after surgery. One decade after surgery the ICER per patient/year was €−9973 (−18,798; −6752) for postoperative SSA treatment and €−31,733 (−59,812; −21,483) in the case of postoperative pegvisomant treatment.

      Conclusions

      In centres without optimal surgical results, preoperative treatment of GH-secreting pituitary macroadenomas with SSA not only shows a significant improvement in the surgical results, but is also highly cost-effective, with an ICER per patient/year one decade after surgery, of between €−9973 (−18,798; −6752) and €−31,733 (−59,812; −21,483) for SSA and pegvisomant respectively.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Melmed S.
        Acromegaly pathogenesis and treatment.
        J Clin Invest. 2009; 119: 3189-3202
        • Colao A.
        • Auriemma R.S.
        • Lombardi G.
        • Pivonello R.
        Resistance to somatostatin analogs in acromegaly.
        Endocr Rev. 2011; 32: 247-271
        • Katznelson L.
        Approach to the patient with persistent acromegaly after pituitary surgery.
        J Clin Endocrinol Metab. 2010; 95: 4114-4123
        • Sandret L.
        • Maison P.
        • Chanson P.
        Place of cabergoline in acromegaly: a meta-analysis.
        J Clin Endocrinol Metab. 2011; 96: 1327-1335
        • Giustina A.
        • Chanson P.
        • Kleinberg D.
        • Bronstein M.D.
        • Clemmons D.R.
        • Klibanski A.
        • et al.
        Expert consensus document: a consensus on the medical treatment of acromegaly.
        Nat Rev Endocrinol. 2014; 10: 243-248
        • Katznelson L.
        • Laws Jr., E.R.
        • Melmed S.
        • Molitch M.E.
        • Murad M.H.
        • Utz A.
        • et al.
        Acromegaly: an endocrine society clinical practice guideline.
        J Clin Endocrinol Metab. 2014; 99: 3933-3951
        • Ben-Shlomo A.
        • Sheppard M.C.
        • Stephens J.M.
        • Pulgar S.
        • Melmed S.
        Clinical, quality of life, and economic value of acromegaly disease control.
        Pituitary. 2011; 14: 284-294
        • Melmed S.
        • Colao A.
        • Barkan A.
        • Molitch M.
        • Grossman A.B.
        • Kleinberg D.
        • et al.
        Guidelines for acromegaly management: an update.
        J Clin Endocrinol Metab. 2009; 94: 1509-1517
        • Biermasz N.R.
        • Roelfsema F.
        • Pereira A.M.
        • Romijn J.A.
        Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.
        Expert Rev Pharmacoecon Outcomes Res. 2009; 9: 223-234
        • Jane J.A.
        • Starke R.M.
        • Elzoghby M.A.
        • Reames D.L.
        • Payne S.C.
        • Thorner M.O.
        • et al.
        Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome.
        J Clin Endocrinol Metabol. 2011; 96: 2732-2740
        • Wang Y.Y.
        • Higham C.
        • Kearney T.
        • Davis J.
        • Trainer P.
        • Gnanalingham K.K.
        Acromegaly surgery in Manchester revisited—the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission.
        Clin Endocrinol (Oxf). 2012; 76: 399-406
        • Bex M.
        • Abs R.
        • T'Sjoen G.
        • Mockel J.
        • Velkeniers B.
        • Muermans K.
        • et al.
        AcroBel—the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects.
        Eur J Endocrinol. 2007; 157: 399-409
        • Schofl C.
        • Franz H.
        • Grussendorf M.
        • Honegger J.
        • Jaursch-Hancke C.
        • Mayr B.
        • et al.
        Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register.
        Eur J Endocrinol. 2013; 168: 39-47
        • Lissett C.A.
        • Peacey S.R.
        • Laing I.
        • Tetlow L.
        • Davis J.R.
        • Shalet S.M.
        The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma.
        Clin Endocrinol (Oxf). 1998; 49: 653-657
        • Abe T.
        • Ludecke D.K.
        Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre.
        Eur J Endocrinol. 2001; 145: 137-145
        • Stevenaert A.
        • Beckers A.
        Presurgical Octreotide: treatment in acromegaly.
        Metabolism. 1996; 45: 72-74
        • Colao A.
        • Ferone D.
        • Cappabianca P.
        • del Basso De Caro M.L.
        • Marzullo P.
        • Monticelli A.
        • et al.
        Effect of octreotide pretreatment on surgical outcome in acromegaly.
        J Clin Endocrinol Metab. 1997; 82: 3308-3314
        • Carlsen S.M.
        • Lund-Johansen M.
        • Schreiner T.
        • Aanderud S.
        • Johannesen O.
        • Svartberg J.
        • et al.
        Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial.
        J Clin Endocrinol Metab. 2008; 93: 2984-2990
        • Mao Z.G.
        • Zhu Y.H.
        • Tang H.L.
        • Wang D.Y.
        • Zhou J.
        • He D.S.
        • et al.
        Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial.
        Eur J Endocrinol. 2010; 162: 661-666
        • Li Z.Q.
        • Quan Z.
        • Tian H.L.
        • Cheng M.
        Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma.
        J Int Med Res. 2012; 40: 517-524
        • Nunes V.S.
        • Correa J.M.
        • Puga M.E.
        • Silva E.M.
        • Boguszewski C.L.
        Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system.
        Pituitary. 2015; 18: 500-508
        • Kristof R.A.
        • Stoffel-Wagner B.
        • Klingmuller D.
        • Schramm J.
        Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study.
        Acta Neurochir (Wien). 1999; 141: 399-405
        • Biermasz N.R.
        • van Dulken H.
        • Roelfsema F.
        Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls.
        J Clin Endocrinol Metab. 1999; 84: 3551-3555
        • Plockinger U.
        • Quabbe H.J.
        Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
        Acta Neurochir (Wien). 2005; 147 ([discussion 93]): 485-493
        • Losa M.
        • Mortini P.
        • Urbaz L.
        • Ribotto P.
        • Castrignano T.
        • Giovanelli M.
        Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates.
        J Neurosurg. 2006; 104: 899-906
        • Shen M.
        • Shou X.
        • Wang Y.
        • Zhang Z.
        • Wu J.
        • Mao Y.
        • et al.
        Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study.
        Endocr J. 2010; 57: 1035-1044
        • Fougner S.L.
        • Bollerslev J.
        • Svartberg J.
        • Oksnes M.
        • Cooper J.
        • Carlsen S.M.
        Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial.
        Eur J Endocrinol. 2014; 171: 229-235
        • Katznelson L.
        • Atkinson J.L.
        • Cook D.M.
        • Ezzat S.Z.
        • Hamrahian A.H.
        • Miller K.K.
        American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly—2011 update.
        Endocr Pract. 2011; 17: 1-44
        • Pita-Gutierrez F.
        • Pertega-Diaz S.
        • Pita-Fernandez S.
        • Pena L.
        • Lugo G.
        • Sangiao-Alvarellos S.
        • et al.
        Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis.
        PLoS One. 2013; 8 ([e61523])
        • Briggs A.H.
        • Wonderling D.E.
        • Mooney C.Z.
        Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.
        Health Econ. 1997; 6: 327-340
        • Giustina A.
        • Mazziotti G.
        • Torri V.
        • Spinello M.
        • Floriani I.
        • Melmed S.
        Meta-analysis on the effects of octreotide on tumor mass in acromegaly.
        PLoS One. 2012; 7 ([e36411])
        • Caron P.J.
        • Bevan J.S.
        • Petersenn S.
        • Flanagan D.
        • Tabarin A.
        • Prévost G.
        • et al.
        Tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.
        J Clin Endocrinol Metab. 2014; 99: 1282-1290
        • Annamalai A.K.
        • Webb A.
        • Kandasamy N.
        • Elkhawad M.
        • Moir S.
        • Khan F.
        • et al.
        A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy.
        J Clin Endocrinol Metabol. 2013; 98: 1040-1050
        • Chahal H.S.
        • Trivellin G.
        • Leontiou C.A.
        • Alband N.
        • Fowkes R.C.
        • Tahir A.
        • et al.
        Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.
        J Clin Endocrinol Metabol. 2012; 97: E1411-E1420
        • Casar-Borota O.
        • Heck A.
        • Schulz S.
        • Nesland J.M.
        • Ramm-Pettersen J.
        • Lekva T.
        • et al.
        Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide.
        J Clin Endocrinol Metabol. 2013; 98: E1730-E1739
        • Maiza J.C.
        • Vezzosi D.
        • Matta M.
        • Donadille F.
        • Loubes-Lacroix F.
        • Cournot M.
        • et al.
        Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.
        Clin Endocrinol (Oxf). 2007; 67: 282-289
        • Minniti G.
        • Scaringi C.
        • Amelio D.
        • Maurizi Enrici R.
        Stereotactic irradiation of GH-secreting pituitary adenomas.
        Int J Endocrinol. 2012; 2012: 482861
        • Jallad R.S.
        • Bronstein M.D.
        The place of medical treatment of acromegaly: current status and perspectives.
        Expert Opin Pharmacother. 2013; 14: 1001-1015
        • Didoni G.
        • Grottol S.
        • Gasco V.
        • Battistini M.
        • Ferone D.
        • Giusti M.
        • et al.
        Cost-of-illness study in acromegalic patients in Italy.
        J Endocrinol Invest. 2004; 27: 1034-1039
        • Luque-Ramirez M.
        • Paramo C.
        • Varela da Costa C.
        • Garcia-Mayor R.V.
        Cost of management of invasive growth hormone-secreting macroadenoma.
        J Endocrinol Invest. 2007; 30: 541-545
        • Wilson L.S.
        • Shin J.L.
        • Ezzat S.
        Longitudinal assessment of economic burden and clinical outcomes in acromegaly.
        Endocr Pract. 2001; 7: 170-180
        • Valentim J.
        • Passos V.
        • Mataveli F.
        • Calabro A.
        Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil.
        Arq Bras Endocrinol Metabol. 2008; 52: 1452-1460
        • Roset M.
        • Merino-Montero S.
        • Luque-Ramirez M.
        • Webb S.M.
        • Lopez-Mondejar P.
        • Salinas I.
        • et al.
        Cost of clinical management of acromegaly in Spain.
        Clin Drug Investig. 2012; 32: 235-245
        • Moore D.J.
        • Adi Y.
        • Connock M.J.
        • Bayliss S.
        Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation.
        BMC Endocr Disord. 2009; 9: 20
        • Giustina A.
        • Chanson P.
        • Bronstein M.D.
        • Klibanski A.
        • Lamberts S.
        • Casanueva F.F.
        • et al.
        A consensus on criteria for cure of acromegaly.
        J Clin Endocrinol Metab. 2010; 95: 3141-3148
        • Dekkers O.M.
        • Biermasz N.R.
        • Pereira A.M.
        • Romijn J.A.
        • Vandenbroucke J.P.
        Mortality in acromegaly: a metaanalysis.
        J Clin Endocrinol Metab. 2008; 93: 61-67
        • Sesmilo G.
        • Gaztambide S.
        • Venegas E.
        • Pico A.
        • Del Pozo C.
        • Blanco C.
        • et al.
        Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA).
        Pituitary. 2013; 16: 115-121
        • Molitch M.E.
        Clinical manifestations of acromegaly.
        Endocrinol Metab Clin North Am. 1992; 21: 597-614
        • Beckers A.
        Does preoperative somatostatin analog treatment improve surgical cure rates in acromegaly? A new look at an old question.
        J Clin Endocrinol Metab. 2008; 93: 2975-2977
        • Heron I.
        • Thomas F.
        • Dero M.
        • Gancel A.
        • Ruiz J.M.
        • Schatz B.
        • et al.
        Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly.
        J Clin Endocrinol Metab. 1993; 76: 721-727
        • Melmed S.
        • Casanueva F.
        • Cavagnini F.
        • Chanson P.
        • Frohman L.A.
        • Gaillard R.
        • et al.
        Consensus statement: medical management of acromegaly.
        Eur J Endocrinol. 2005; 153: 737-740
        • Jacob J.J.
        • Bevan J.S.
        Should all patients with acromegaly receive somatostatin analogue therapy before surgery, and if so, for how long?.
        Clin Endocrinol (Oxf). 2014; 81: 812-817
        • Barker 2nd, F.G.
        • Klibanski A.
        • Swearingen B.
        Transsphenoidal surgery for pituitary tumors in the United States, 1996–2000: mortality, morbidity, and the effects of hospital and surgeon volume.
        J Clin Endocrinol Metab. 2003; 88: 4709-4719